ASCO Annual Meeting: Lung Cancer

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy.

Study data shows Ibtrozi provides rapid symptom relief and stable brain health for patients with advanced ROS1-positive lung cancer.

Sac-TMT plus Keytruda helped patients with PD-L1–positive advanced NSCLC live longer without their cancer worsening and increased response rates versus Keytruda alone.

ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.